Navigation Links
Cytel's Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
Date:6/23/2008

Trial design and implementation pioneers from Cytel join peers in examining

the rise of adaptive study approaches and overcoming the remaining

challenges to wider adoption

CAMBRIDGE, Mass., June 23 /PRNewswire/ -- Cytel's renowned adaptive trial design and implementation experts Cyrus Mehta (http://www.cytel.com) and Judith Quinlan (http://www.cytel.com) will lead workshops and case study reviews at the Annual Meeting of the Drug Information Association (DIA) June 22 - 25, 2008 in Boston.

Adaptive trials are finding ever-increasing acceptance by sponsors and regulators seeking to improve clinical development productivity and reduce the rate of trial failures. Combining a wealth of experience designing and implementing adaptive trials together with over 20 years developing software for trial design, simulation and analysis, Cytel's clinical innovation know- how is unmatched.

At this year's DIA meeting, senior managers, clinicians, statisticians and trial logistics professionals from the biopharmaceutical industry will share their recent experiences with adaptive trials, and the insights gained on planning and conducting the next generation of adaptive studies.

Speaking on the latest innovative trial techniques and tools will be Cytel Co-Founder and President, Dr. Cyrus Mehta, and Vice President of Adaptive Trials, Judith Quinlan.

Dr. Mehta will join Dr. William Byrom, Vice President, Product Strategy at trial technology leader ClinPhone, for the workshop "Adaptive Design in Clinical Research", June 23, 10:30A - 12:30P.

Reporting on the PhRMA Working Group for Adaptive Trials efforts to chronicle trial innovation successes, Cytel's Judith Quinlan presents "Are You Ready for Adaptive Clinical Development? Examples, Case Studies, Successes" on June 24, 8:30A - 9:30A.
See the complete DIA meeting website

http://www.diahome.org/DIAHome/FlagshipMeetings/home.aspx?meetingid=14235

and the DIA's blog site

http://www.diaannual.com/

Dr. Mehta and Vice President Quinlan are available for interviews following the DIA conference.


'/>"/>
SOURCE Cytel, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... CITY, Calif., Feb. 8, 2016  Aoxing Pharmaceutical Company, Inc. (NYSE ... fiscal year 2016, ended December 31, 2015, the Company achieved ... recorded in the same quarter in fiscal 2015. ... in Q2 of fiscal year 2016 was $2,068,635, or $.03 ... or $.01 per share, in the Q2 of fiscal year ...
(Date:2/8/2016)... Feb. 8, 2016 ... of the "Label-Free Detection Market by ... 2020" report to their offering. ... addition of the "Label-Free Detection Market ... to 2020" report to their offering. ...
(Date:2/8/2016)...  HemaFlo Therapeutics, Inc. announced today that the United States ... 9,119,880 covering the use of NephroFlow to treat acute kidney ... founder, said, "We are pleased to secure our rights to ... , PhD, HemaFlo,s founder, said, "We are pleased to secure ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ...
Breaking Medicine Technology:
(Date:2/8/2016)... , ... February 08, 2016 , ... Discover the Rocky ... over 1,400 booths and 700 companies. Attendees also get to see the most ... Colorado Garden & Home Show , at the Colorado Convention Center - 700 14th ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua Rosenthal, ... how healthcare companies can use newly released government data on populations and physicians ... and intervene and capture the value they create to succeed in new economic ...
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... the ability to correct pelvic organ prolapse with the latest techniques and the ... at greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , ... with an estimated 5000 perioperative nurses in attendance to study the latest ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... eating disorder treatment helps to reduce the frequency and level of relapse. ... Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of the ...
Breaking Medicine News(10 mins):